Novanta (NASDAQ:NOVT) Updates Q3 2026 Earnings Guidance

Novanta (NASDAQ:NOVT) issued an update on its third quarter 2026 earnings guidance on Wednesday. The company provided earnings per share guidance of 0.950-1.000 for the period, compared to the consensus earnings per share estimate of 0.940. The company issued revenue guidance of $300.0 million-$304.0 million, compared to the consensus revenue estimate of $263.1 million. Novanta also updated its FY 2026 guidance to 3.680-3.740 EPS.

Novanta Stock Performance

NASDAQ:NOVT traded down $6.37 on Wednesday, hitting $153.12. The company’s stock had a trading volume of 548,040 shares, compared to its average volume of 466,732. Novanta has a one year low of $98.27 and a one year high of $171.85. The firm has a market capitalization of $5.78 billion, a P/E ratio of 110.96 and a beta of 1.68. The stock has a fifty day moving average of $153.85 and a two-hundred day moving average of $141.21. The company has a current ratio of 3.56, a quick ratio of 2.69 and a debt-to-equity ratio of 0.15.

Novanta (NASDAQ:NOVT) last issued its earnings results on Wednesday, August 5th. The technology company reported $0.89 EPS for the quarter, topping the consensus estimate of $0.83 by $0.06. The company had revenue of $265.81 million during the quarter, compared to the consensus estimate of $262.30 million. Novanta had a return on equity of 12.06% and a net margin of 5.35%.The firm’s revenue for the quarter was up 10.3% compared to the same quarter last year. During the same period in the previous year, the company posted $0.76 EPS. Novanta has set its FY 2026 guidance at 3.680-3.740 EPS and its Q3 2026 guidance at 0.950-1.000 EPS. Research analysts predict that Novanta will post 3.59 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several equities analysts have recently weighed in on the stock. Robert W. Baird set a $180.00 price objective on shares of Novanta in a research report on Tuesday, June 9th. Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Novanta in a report on Wednesday, July 15th. Finally, Wall Street Zen cut Novanta from a “buy” rating to a “hold” rating in a research report on Saturday. One analyst has rated the stock with a Buy rating and two have given a Hold rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus price target of $180.00.

Insider Transactions at Novanta

In other Novanta news, CEO Matthijs Glastra sold 6,500 shares of the stock in a transaction dated Thursday, July 2nd. The shares were sold at an average price of $161.13, for a total transaction of $1,047,345.00. Following the sale, the chief executive officer directly owned 29,761 shares in the company, valued at $4,795,389.93. This represents a 17.93% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 1.20% of the stock is owned by insiders.

Institutional Trading of Novanta

Large investors have recently bought and sold shares of the business. CIBC Bancorp USA Inc. acquired a new stake in shares of Novanta in the 3rd quarter valued at approximately $386,000. Laurion Capital Management LP bought a new position in Novanta in the 4th quarter valued at approximately $384,000. Osaic Holdings Inc. lifted its stake in Novanta by 471.7% in the 2nd quarter. Osaic Holdings Inc. now owns 2,893 shares of the technology company’s stock valued at $371,000 after purchasing an additional 2,387 shares during the last quarter. Brooklyn Investment Group acquired a new stake in Novanta in the fourth quarter valued at approximately $353,000. Finally, Mercer Global Advisors Inc. ADV bought a new stake in shares of Novanta during the fourth quarter worth $314,000. 98.35% of the stock is owned by institutional investors and hedge funds.

About Novanta

Novanta, Inc (NASDAQ: NOVT) is a global technology company that designs and manufactures precision components, subsystems and software used in advanced photonics and motion control applications. The company serves customers in the medical device and advanced industrial markets, supplying critical technologies for diagnostics and therapeutic systems, semiconductor and electronics manufacturing, and scientific instrumentation. Novanta’s product portfolio includes laser control modules, optics, beam delivery systems, high-precision motors, actuators, stages, and fluidics solutions designed to meet stringent accuracy and reliability requirements.

Novanta’s Photonics segment delivers laser and energy delivery components that enable minimally invasive surgical procedures and diagnostic imaging.